OSE Immunotherapeutics Announces First Peer-Reviewed Publication in “Science Advances” on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation

NEXT STORY
AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
PREV STORY
Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program

author_avatar
NASDAQ Market News

P3 Health Partners Closes Business Combination with Foresight Acquisition Corp. and Will Begin Trading on the Nasdaq

author_avatar
NASDAQ Market News

Republic First Bancorp, Inc. Reports Third Quarter Financial Results

author_avatar
NASDAQ Market News